Business Context and Reporting Period
This Form 8-K filing by AcelRx Pharmaceuticals, Inc. (ACRX) reports events occurring on October 1, 2020, with the report dated October 6, 2020. The filing details a strategic restructuring of the company's commercial partnerships regarding its product DSUVIA (sufentanil sublingual tablet).
Key Financial Metrics
This filing is a Current Report regarding material agreements and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes Versus Prior Period
- Termination of Co-Promotion: The Company terminated the Co-Promotion Agreement with Tetraphase Pharmaceuticals, Inc. (a subsidiary of La Jolla Pharmaceutical Company) effective September 30, 2020. This agreement previously covered the co-promotion of DSUVIA and XERAVA (eravacycline).
- New Promotion Agreement: A new Promotion Agreement was entered into with La Jolla and Tetraphase, effective September 30, 2020. Under this arrangement, La Jolla assumes responsibility for detailing and promoting DSUVIA.
- Scope Change: The Company will no longer detail and promote XERAVA under the new agreement. AcelRx retains responsibility for developing marketing strategy, creating promotional materials, and handling sales and distribution for its products.
Guidance, Outlook, and Material Terms
- Agreement Term: The new Promotion Agreement has a two-year term.
- Termination Rights: AcelRx may terminate the agreement with 30 days' notice. La Jolla may terminate after one year with 30 days' notice, or earlier in the event of a change of control or management at AcelRx. Either party may terminate for uncured material breach or insolvency.
- Compensation Structure: AcelRx will pay La Jolla a revenue share on net sales of products in covered territories (excluding certain accounts). These territories do not overlap with AcelRx's existing sales force.
- Performance Penalty: If La Jolla fails to meet detailing requirements in a calendar quarter, it must pay AcelRx a royalty on net sales of XERAVA in the United States for that quarter.
- Management Oversight: A joint marketing and sales committee will oversee La Jolla's promotion activities and develop marketing plans.
Important Facts for Investor Verification
- Verify the specific revenue share percentage and royalty rates in the full text of the Promotion Agreement, which is referenced but not included in this filing.
- Confirm the definition of "excluded accounts" and the specific sales territories covered by La Jolla to assess potential cannibalization of AcelRx's direct sales force.
- Monitor La Jolla's ability to meet the minimum sales call requirements to avoid triggering the royalty payment on XERAVA sales.
- Review the upcoming Form 10-Q for the quarter ending September 30, 2020, for the full text of the Promotion Agreement and any financial impact disclosures.